Cellenkos scores FDA orphan drug designation for CK0804 in rare blood cancer
Receiving Orphan Drug Designation is an important milestone in the clinical development of CK0804 for myelofibrosis
Receiving Orphan Drug Designation is an important milestone in the clinical development of CK0804 for myelofibrosis
The therapy was well tolerated through Week 24, with a safety profile consistent with Alumis’ Phase 2 data
Blood tests measuring biomarkers such as p-tau217 are emerging as accurate, accessible alternatives
ADHD is a common, chronic neurodevelopmental disorder that often begins in childhood and can persist into adulthood
Sevabertinib is an oral, reversible tyrosine kinase inhibitor (TKI) that directly targets HER2 mutations
The MAGiC catheter is designed for robotically-navigated cardiac ablation procedures
The trial’s primary endpoint is the mean change in HbA1c from baseline, while secondary endpoints include changes in fasting blood glucose, body weight, and overall safety
DengiAll will be the first indigenous single-shot dengue vaccine in India and is expected to enter the markets by 2027
WCK 5222 is the first New Chemical Entity (NCE) discovered and developed in India to be submitted for pan-European marketing authorisation
Fasting glucose improved by 12.3 mg/dL, while liver stiffness dropped 23.7%, signaling a direct hepatic benefit
Subscribe To Our Newsletter & Stay Updated